SINTX Technologies Reports 3% Revenue Growth and $2.8 Million Net Loss in Q1 2026

SINTX Technologies, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $380,000, a 3% increase from $369,000 in the same period of 2025. The growth was primarily driven by a 3% rise in product revenue, which reached $300,000, and a 3% increase in grant and contract revenue to $80,000. However, when accounting for the impact of the divestiture of its TA&T subsidiary, which reduced revenue by $109,000, the underlying revenue growth was more pronounced, with total revenue increasing by 46% and product revenue rising by 32%. Despite this revenue growth, SINTX reported a net loss of $2.8 million for the quarter, compared to a loss of $2.3 million in the prior year, reflecting a 23% increase in losses.

The company's operating expenses rose to $3.4 million, a 34% increase from $2.5 million in the previous year. This increase was largely attributed to a significant rise in general and administrative expenses, which surged by 92% to $2.5 million, driven by higher headcount-related costs and the reallocation of overhead costs from research and development. Conversely, research and development expenses decreased by 67% to $364,000, as the company shifted its focus towards commercialization efforts. The overall loss from operations increased by 35% to $3.2 million, indicating challenges in managing costs alongside revenue growth.

SINTX has made strategic moves to enhance its operational efficiency, including the recent FDA 510(k) clearance for its SiNAPTIC Foot & Ankle Osteotomy Wedge System, which is expected to contribute to revenue growth in the medical device sector. The company also entered into an At The Market (ATM) offering agreement in October 2025, allowing it to raise up to $6.4 million through the sale of common stock. As of March 31, 2026, SINTX had raised $0.7 million under this program, with an additional $0.5 million raised shortly after the quarter ended. These initiatives are part of SINTX's broader strategy to focus on high-growth areas within healthcare, leveraging its proprietary silicon nitride materials.

Operationally, SINTX's cash and cash equivalents decreased to $1.9 million from $4.1 million at the end of 2025, reflecting a net cash outflow of $2.5 million from operating activities during the quarter. The company reported an accumulated deficit of $295 million as of March 31, 2026. Despite the ongoing financial challenges, management remains optimistic about the potential for increased revenues from its industrial and medical product lines, particularly as it continues to develop and commercialize its silicon nitride-based technologies.

Looking ahead, SINTX acknowledges substantial doubt regarding its ability to continue as a going concern for at least the next 12 months, contingent on its ability to generate increased revenues, achieve profitability, and secure additional financing. The company is actively seeking opportunities to raise funds through equity and debt financing, although it recognizes that such funding may not be guaranteed or available on favorable terms. The management team is committed to executing its strategic objectives to enhance shareholder value while navigating the complexities of the current market environment.